These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 3020821)

  • 1. Characterization and immunogenicity of HSV-1 antigens obtained following zwitterionic detergent treatment.
    Mukhlis FA; Jennings R; Stephenson TJ; Quasim T; Potter CW
    Vaccine; 1986 Sep; 4(3):191-6. PubMed ID: 3020821
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative studies of HSV-1 antigens solubilised from infected cells by using non-ionic or zwitterionic detergents.
    Jennings R; Erturk M
    J Med Virol; 1990 Jun; 31(2):98-108. PubMed ID: 2167352
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Zwitterionic detergent solubilisation of HSV-1 surface antigens.
    Jennings R; Quasim T; Sharrard RM; Hockley D; Potter CW
    Arch Virol; 1988; 98(3-4):137-53. PubMed ID: 2831853
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protection and serum antibody responses in guinea-pigs and mice immunized with HSV-1 antigen preparations obtained using different detergents.
    Ertürk M; Welch MJ; Phillpotts RJ; Jennings R
    Vaccine; 1989 Oct; 7(5):431-6. PubMed ID: 2554607
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Latent HSV-1 infection in mice immunized with a zwitterionic detergent-extracted HSV-1 antigen preparation.
    al-Ghamdi A; Jennings R; Bentley H; Potter CW
    Arch Virol; 1989; 108(1-2):19-31. PubMed ID: 2556982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody responses and protection in mice immunized with herpes simplex virus type 1 antigen immune-stimulating complex preparations.
    Ertürk M; Jennings R; Hockley D; Potter CW
    J Gen Virol; 1989 Aug; 70 ( Pt 8)():2149-55. PubMed ID: 2769234
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Purification of herpes simplex virus glycoproteins B and C using monoclonal antibodies and their ability to protect mice against lethal challenge.
    Roberts PL; Duncan BE; Raybould TJ; Watson DH
    J Gen Virol; 1985 May; 66 ( Pt 5)():1073-85. PubMed ID: 2582080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody responses, cytokine levels and protection of mice immunised with HSV-2 antigens formulated into NISV or ISCOM delivery systems.
    Mohamedi SA; Brewer JM; Alexander J; Heath AW; Jennings R
    Vaccine; 2000 Apr; 18(20):2083-94. PubMed ID: 10715522
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Passive transfer of anti-herpes simplex virus type 2 monoclonal and polyclonal antibodies protect against herpes simplex virus type 1-induced but not herpes simplex virus type 2-induced stromal keratitis.
    Ritchie MH; Oakes JE; Lausch RN
    Invest Ophthalmol Vis Sci; 1993 Jul; 34(8):2460-8. PubMed ID: 8392037
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mucosal and systemic antiviral antibodies in mice inoculated intravaginally with herpes simplex virus type 2.
    McDermott MR; Brais LJ; Evelegh MJ
    J Gen Virol; 1990 Jul; 71 ( Pt 7)():1497-504. PubMed ID: 2165134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protective immunization of mice with specific HSV-1 glycoproteins.
    Chan WL
    Immunology; 1983 Jun; 49(2):343-52. PubMed ID: 6303950
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Escherichia coli-derived envelope protein gD but not gC antigens of herpes simplex virus protect mice against a lethal challenge with HSV-1 and HSV-2.
    Bröker M; Abel KJ; Köhler R; Hilfenhaus J; Amann E
    Med Microbiol Immunol; 1990; 179(3):145-59. PubMed ID: 2169577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Yeast-derived glycoprotein B-1 of herpes simplex virus (HSV) as a candidate for an HSV vaccine.
    Kino Y
    Adv Exp Med Biol; 1990; 278():183-90. PubMed ID: 1963033
    [No Abstract]   [Full Text] [Related]  

  • 14. Intratypic variation of herpes simplex virus type 2 isolates detected by monoclonal antibodies against viral glycoproteins.
    Bhattarakosol P; Yoosook C; Cross A
    Arch Virol; 1990; 115(1-2):89-100. PubMed ID: 1701081
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of neutralizing antibody against varicella-zoster virus (VZV) by VZV gp3 and cross-reactivity between VZV gp3 and herpes simplex viruses gB.
    Kitamura K; Namazue J; Campo-Vera H; Ogino T; Yamanishi K
    Virology; 1986 Feb; 149(1):74-82. PubMed ID: 2418583
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity of influenza and HSV-1 mixed antigen ISCOMs in mice.
    Ghazi HO; Erturk M; Stannard LM; Faulkner M; Potter CW; Jennings R
    Arch Virol; 1995; 140(6):1015-31. PubMed ID: 7611875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant-independent enhanced immune responses to recombinant herpes simplex virus type 1 glycoprotein D by fusion with biologically active interleukin-2.
    Hazama M; Mayumi-Aono A; Asakawa N; Kuroda S; Hinuma S; Fujisawa Y
    Vaccine; 1993; 11(6):629-36. PubMed ID: 8391739
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of monoclonal antibody directed against herpes simplex virus glycoproteins to protect mice against acute virus-induced neurological disease.
    Dix RD; Pereira L; Baringer JR
    Infect Immun; 1981 Oct; 34(1):192-9. PubMed ID: 6271681
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monoclonal Antibodies, Derived from Humans Vaccinated with the RV144 HIV Vaccine Containing the HVEM Binding Domain of Herpes Simplex Virus (HSV) Glycoprotein D, Neutralize HSV Infection, Mediate Antibody-Dependent Cellular Cytotoxicity, and Protect Mice from Ocular Challenge with HSV-1.
    Wang K; Tomaras GD; Jegaskanda S; Moody MA; Liao HX; Goodman KN; Berman PW; Rerks-Ngarm S; Pitisuttithum P; Nitayapan S; Kaewkungwal J; Haynes BF; Cohen JI
    J Virol; 2017 Oct; 91(19):. PubMed ID: 28701403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of solubilized herpes simplex virus membrane antigens in diffusion in gel-enzyme-linked immunosorbent assay (DIG-ELISA).
    Jeansson S; Elwing H; Nygren H; Olofsson S
    J Virol Methods; 1982 Apr; 4(3):167-76. PubMed ID: 6281290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.